The kidney is the most transplanted organ worldwide, followed by the liver and the heart. In 2023, there were a total of ******* organ transplants worldwide. Organ transplantation is frequently the best or only treatment for end stage organ failure, although transplantation can be challenging and complex. Kidney transplantation Kidney transplantation, or renal transplantation, is by far the most common type of organ transplantation worldwide. Although end stage renal disease can be treated through other means, such as dialysis, kidney transplantation is largely viewed as the best treatment option. Most kidney transplants are done in the Americas and in Europe, where there are a larger number of donors and better access to such procedures. Organ donors Organs can be donated either from a living donor or a deceased donor, depending on the type of organ. Organ donation frequency is different from country to country, as laws that permit or refuse donation vary. Spain, the United States, and Portugal have the highest rates of deceased organ donors worldwide; however, there are still high numbers of patients waiting for organ transplants. In the United States alone, there are almost *** thousand candidates waiting for organ donations, the majority of which require a kidney transplantation.

In 2023, Spain had the highest rate of deceased organ donors among select OECD countries with ** people per million population. Organ donation is an important life-saving method for people with organ failure and late-stage disease. Organ Donation Organs can be donated from either living or deceased persons, depending on the type and supply of select organs. Each country is responsible for organizing its own organ transplant systems. In the United States, for example, organ donors are required to register to a national database. A lack of organs available for transplant remains a problem in many countries around the world. In the United States, there are over *** thousand people currently waiting for an organ transplant. Global organ donations The total number of transplants performed each year has been on the rise. Organ donations globally reached over *** thousand in the year 2023, with kidneys accounting for a majority of the organs transplanted. The Americas and Europe make up the largest proportion of global kidney transplants, while Africa has the lowest number. The Americans and Europe also have the highest proportions of global liver transplants.

France had a rate of around ** patients with organ transplantations per million population in 2023. Organ donation can be given through both a deceased and living donor if blood and oxygen are flowing through the organs until the time of recovery to ensure viability. This statistic displays the rate of patients with transplanted organs in selected countries worldwide in 2023.

Snapshot img { margin: 10px !important; } Global transplant diagnostics market forecast

According to the transplant diagnostics industry analysis, Technavio’s market research analyst predicts the global transplant diagnostics market to grow at a CAGR of more than 6% by 2020. Various governmental and non-governmental organizations are conducting awareness programs to spread the knowledge about organ transplantation. Awareness of organ donation can help meet the demand for the number of required transplantation. Though many people support the cause, very few donate organs. Organizations need to spread awareness about the benefits of organ transplantation to meet the demand for a donor organ and reduce the mortality rate. The rise in public awareness of organ donation will boost the growth prospects of this market during the forecast period.

The growing demand and increasing use of transplant diagnostics have propelled several manufacturers to come up with new products in the market. Most of these new products introduced have received regulatory approvals, particularly FDA approval, and are accessible to both individuals and medical personnel. For instance, ThermoFisher Scientific introduced the NXType NGS HLA typing assay that includes molecular typing products such as SSO, SSP, and SBT technologies. Recently, Illumina introduced Conexio's HLA typing solutions that allow researchers to analyze genomic variants that cause complications during transplants.

Segmentation by screening and analysis of the transplant diagnostics market

Pre-transplant diagnostics
Post-transplant diagnostics

The post-transplant diagnostics segment dominated the market in 2015 and accounted for more than 59% of the total market share. The use of post-transplant diagnostics is high as many people undergo regular biopsies in the initial months after organ transplantation. The most popular device for carrying out this procedure is AlloMap system which can be used between six months and five years after heart transplantation to check the presence of acute cellular rejections in high-risk patients aged above 15 years. The rise in organ transplantations has increased the use of these procedures, thereby augmenting the growth prospects for this segment in the coming years.

Geographical segmentation and analysis of the transplant diagnostics market

Americas
APAC
EMEA

Based on the transplant diagnostics market outlook, the Americas will be the dominating region in the market over the next four years and is expected to occupy 53% of the overall market share. Much of this market’s growth can be attributed to the rising procurement of transplant diagnostic instruments among medical facilities as they are considered one-time investment products and have longer shelf-life than consumables. With the rising prevalence of chronic diseases, the volume of organ transplantation will increase, thereby increasing the demand for transplant diagnostics in the coming years.

Competitive landscape and key vendors

The market has the presence of many global and local providers who are implementing various strategies to gain a competitive edge over their peers. The established vendors have greater brand recognition, financial and technical resource, and product development and marketing capabilities, which has intensified the competition in the market. Several vendors are shifting their operations to APAC owing to the huge growth opportunities in the region. Also, vendors are developing their relationship with transplant centers and hospitals to gain maximum market reach.

Key vendors in the market are

Bio-Rad Laboratories
CareDx
Illumina
Immucor
Linkage Biosciences
ThermoFisher

Other prominent vendors in the transplant diagnostics market are Abbott Laboratories, Becton, Dickinson, Danaher, F. Hoffmann-La Roche, HistoGenetics, Ortho Clinical Diagnostics, Oxford Immunotec, Qiagen, Siemens, Sigma-Aldrich, and Tosoh Bioscience.

Key questions answered in the report include

What will the market size and the growth rate be in 2020?
What are the key factors driving the global transplant diagnostics market?
What are the key market trends impacting the growth of the global transplant diagnostics market?
What are the challenges to market growth?
Who are the key vendors in the global transplant diagnostics market?
What are the market opportunities and threats faced by the vendors in the global transplant diagnostics market?
Trending factors influencing the market shares of the Americas, APAC, and EMEA.
What are the key outcomes of the five forces analysis of the global transplant diagnostics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

Global Transplantation Market 2015-2019
Global Ventricular Assist Devices (VAD) Market 2015-2019

The rate of kidney transplant procedures in Portugal has increased since 2020. In 2023, 53.6 kidney transplants per million population were carried out in the country. Liver transplants were the second-most carried out transplant procedure in Portugal at over 24 per million, followed by heart. Waiting list in Portugal There were 1,137 patients waiting for a kidney transplant in Portugal in 2023, a decrease from 2019 when there were around 2,300 patients active on the waiting list. To compare, the number of patients on a liver transplantation waiting list exceeded 300 in 2023. Activity compared to Europe Compared to the rest of the European Union (EU) countries, Portugal had a fairly high rate of kidney transplants. Additionally, Portugal had a high rate of liver transplant procedures, at over 24 per million population in 2023. The highest figures in the region were recorded in Belgium, Italy, Spain, and Croatia.

The global organ transplant immunosuppressant drugs market is a significant and rapidly expanding sector, projected to reach a substantial size. While the provided data states a market size of $6,500.7 million in an unspecified year, we can infer this represents a point within the 2019-2024 historical period based on the study's timeframe (2019-2033). Let's assume, for illustrative purposes, this $6,500.7 million figure reflects the market size in 2024. To estimate the Compound Annual Growth Rate (CAGR), we need additional data points. However, considering the continuous advancements in transplantation techniques and the increasing prevalence of organ failure necessitating transplants, a conservative estimate of CAGR between 5% and 7% for the forecast period (2025-2033) is reasonable. This implies strong market growth driven by several factors. Key drivers include the rising incidence of chronic diseases leading to organ failure, technological advancements resulting in improved transplant success rates, and the expansion of organ transplant programs globally. Market trends indicate a shift towards personalized medicine, with increasing focus on developing targeted therapies to minimize side effects and enhance efficacy. However, the market faces certain restraints including the high cost of immunosuppressant drugs, potential for adverse events, and challenges related to organ availability. The market is segmented by drug type (antibodies, antiproliferative agents, calcineurin inhibitors, mTOR inhibitors, steroids) and transplant type (bone marrow, heart, kidney, liver, lung). Major players like Roche, Sanofi, Astellas Pharma, GlaxoSmithKline, Novartis, Pfizer, and Veloxis Pharmaceuticals are actively involved in research and development, shaping the competitive landscape. The regional distribution of the market is expected to reflect global trends in healthcare expenditure and organ transplantation prevalence, with North America and Europe maintaining a significant share.

In 2023/24, 265 patients died on the organ transplant waiting list while waiting for a kidney transplant in the United Kingdom (UK), by far the highest number compared to other organs. In this period, 67 and 42 people also died waiting for liver and lung transplants respectively. Transplant situation in the UK The number of people waiting for a kidney transplant in the UK was over 5.3 thousand in 2023, which was the highest for any organ by quite a distance. This was followed by individuals waiting for liver transplants and heart transplants with 663 and 305 patients each respectively. The problem exists is that in 2022/23 the number of potential donors was over four times the number of actual donors in the UK. Survival chances after a transplant In the UK, the one-year survival rate after a kidney transplant is generally good. Since 2005, 99 percent of those receiving a kidney transplant from a living donor survived for at least one-year post-transplant. The survival rates from deceased donors are slightly below, sitting at a 97 percent survival rate for the period 2014 to 2019.

Global Organ Transplant Immunosuppressant Drugs Market is valued to reach USD 5.4 Billion by 2026, exhibiting a CAGR of 3.25% over forecast period 2020-2026. Increasing prevalence of chronic disease, rising patients requiring organ transplantations and technological advancements in organ transplant are the factors augmenting the market growth.

Market Trends, Drivers, Restraints, and Opportunities:

• High prevalence of diseases caused due to organ failure is increasing the number of transplants globally. This, in turn, is driving the growth of the market.
• Rising prevalence of diseases caused due to obesity, alcohol abuse, or congenital ailments are increasing the number of transplantation surgeries, which is further propelling market growth.
• High cost of transplant procedures and short obtain ability of organs are restraining the market growth.
• High demand for organ transplantation is expected to drive the growth of the market.

Scope of the report:

Abstract Introduction: The unprecedented coronavirus disease 2019 (COVID-19) pandemic has affected kidney transplant (KT) recipients, with worldwide fatality rates around 25%. Considering the well-known Brazilian socio-demographic disparities, this report describes for the first time the main outcomes of COVID-19 in KT recipients according to Brazilian geographic regions. Methods: This multicenter national retrospective analysis included data from KT recipients with confirmed COVID-19 between March and November 2020. Results: Thirty-five of the 81 centers (57% of KT activity in Brazil) reported 1,680 patients with COVID-19. The Northeast was the first to reach the peak in the number of infections. The Southeast, due to its population density, contributed with the largest number of patients. Patients had a median age of 52 years, 76% had hypertension and 34% diabetes, 75% were recipients of a deceased donor, and the time interval between diagnosis and transplantation was 5.9 years. In 53% of patients, immunosuppression was adjusted, and clinical support varied according to geographic region. Hospitalization was required for 65% of the patients, 35% of them needed intensive care, 25% mechanical ventilation, and 23% renal replacement therapy. The 90-day overall fatality was 21%, being 23% in the Southeast, 16% in the Northeast, and 19% in the Central-west and South regions. Conclusion: The migratory pattern of the pandemic among KT recipients followed that of the general population and the outcomes were influenced by regional features. COVID-19 in KT recipients was associated with high utilization of health-care resources and higher fatality rates than those reported in the general population.

Snapshot img

Heart Transplantation Therapeutics Market Size 2025-2029

The heart transplantation therapeutics market size is forecast to increase by USD 129.7 million, at a CAGR of 3% between 2024 and 2029.

The market is experiencing significant growth due to the increasing prevalence of ventricular assist devices and cardiovascular diseases, as well as heart failures. The need for organ preservation techniques during transplantation procedures is also driving market expansion. Moreover, the advancement of precision medicine and regenerative medicine is expected to revolutionize the heart transplantation landscape. However, the use of immunosuppressants for preventing organ rejection poses challenges due to their adverse effects, including increased risk of infections and cancer. The market is further influenced by international collaborations for heart transplantation research and development. Blood compatibility issues and ethical concerns are other factors shaping the market dynamics.

What will be the Size of the Heart Transplantation Therapeutics Market During the Forecast Period?

Request Free Sample

The market is specifically focused on heart transplantation therapeutics, is experiencing significant growth due to the increasing prevalence of cardiovascular disease and the ageing population. According to recent statistics, cardiovascular disease is the leading cause of mortality worldwide, with an estimated 17.9 million heart surgeries performed annually. The geriatric population, in particular, is a key driver of this market, as they are more susceptible to heart-related conditions. Heart transplantation remains a viable option for end-stage cardiac patients, with both orthotopic and heterotopic transplantation techniques being utilized. Heart transplant devices, such as heart-lung machines and implantable cardioverter-defibrillators, are essential components of these procedures.
Post-transplant care involves the use of immunosuppressants, anti-infectives, and analgesics to manage complications and ensure graft survival. Organ preservation techniques and advances in immunosuppressive therapies have improved transplant outcomes, leading to a growing number of successful procedures. Additionally, regenerative medicine approaches, including arrhythmia treatment and aneurysm repair, are emerging as potential alternatives to transplantation. The market for heart transplant therapeutics includes sales through hospitals, cardiac centers, hospital pharmacies, retail pharmacies, and online pharmacies.

How is this Heart Transplantation Therapeutics Industry segmented and which is the largest segment?

The heart transplantation therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Immunosuppressants
  Anti-infectives
  Analgesics
  Others


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Type

  Left ventricular assist device (LVAD)
  Heart transplantation
  Implantable cardiac defibrillator (ICD)
  Extracorporeal membrane oxygenation (ECMO)


Indication

  Ischemic heart disease (IHD)
  Dilated cardiomyopathy (DCM)
  Valvular heart disease (VHD)
  Hypertrophic cardiomyopathy (HCM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The immunosuppressants segment is estimated to witness significant growth during the forecast period.

Immunosuppressants play a crucial role in organ transplantation procedures, particularly for non-identical donor-recipient matches. These drugs, including immunosuppressive medications and environmental toxins, prevent the recipient's immune system from rejecting the transplanted organ. Upon transplantation, the new organ is perceived as a foreign agent by the body's defense system, triggering an immune response aimed at damaging or destroying it. Immunosuppressants mitigate this response, enabling the new organ to integrate successfully. The geriatric population, afflicted by cardiovascular diseases such as heart failure, arrhythmias, aneurysms, and cardiomyopathy, often undergo heart transplantation procedures.

Hospitals, cardiac centers, and transplant institutes employ immunosuppressants, immunosuppressive therapies, regenerative medicine approaches, and organ preservation techniques to improve graft survival and enhance the quality of life for transplant recipients. Immunosuppressive drug regimens, antimicrobials, analgesics, and hospital and retail pharmacies are essential components of post-transplant care. Infectious complications, graft vasculopathy, and immunological challenges are ongoing con

The global market for drugs used in organ rejection prophylaxis is a significant and growing sector, projected to reach a value of $5,175.6 million in 2025. This represents a Compound Annual Growth Rate (CAGR) of 3.4% from 2019 to 2033, indicating a steady increase in demand driven by several key factors. The rising prevalence of organ transplantation procedures globally, fueled by advancements in surgical techniques and improved organ preservation methods, is a major contributor to market expansion. Furthermore, an aging population in many developed countries increases the incidence of end-stage organ failure, thus driving demand for transplantation and, consequently, rejection prophylaxis medications. Increased awareness among healthcare professionals and patients regarding the importance of preventing organ rejection is also contributing to market growth. The market is segmented by application (hospital, specialist clinic, other), drug type (oral liquid, injection, capsule), and geographic region. Competitive landscape analysis reveals the presence of major pharmaceutical companies such as Astellas Pharma, Pfizer, Bausch Health, and others, who actively contribute to research, development, and the market supply of these crucial medications. The market is expected to experience further expansion through the introduction of novel, more effective, and safer drugs with improved tolerability profiles. Ongoing research and development efforts are focused on improving the efficacy and safety profiles of existing drugs, as well as developing novel agents targeting specific mechanisms of immune response to transplanted organs. This includes exploring new drug delivery systems for enhanced patient compliance and treatment outcomes. Market growth may also be influenced by factors such as pricing pressures, regulatory hurdles for new drug approvals, and reimbursement policies in different healthcare systems. However, the long-term outlook for the organ rejection prophylaxis drug market remains positive, driven by an increasing need for effective therapies in an expanding transplantation landscape. The consistent growth and market size forecast indicate a considerable investment opportunity for companies involved in this vital area of healthcare.

The global organ rejection prophylaxis treatment market is a significant and rapidly growing sector within the pharmaceutical industry, driven by increasing organ transplantation procedures worldwide and a rising prevalence of chronic diseases requiring transplantation. While precise market size figures for 2025 are not provided, a logical estimation can be made. Considering a typical CAGR in the pharmaceutical sector around 5-7% and a plausible starting market size (let's assume $5 billion in 2019), a reasonable estimate for the 2025 market size would be in the range of $6.5 billion to $7.5 billion. This substantial market value underscores the significant investment and ongoing research dedicated to improving organ rejection prophylaxis treatments. Key drivers include the development of novel immunosuppressants with improved efficacy and reduced side effects, technological advancements in transplantation procedures, and an expanding geriatric population susceptible to organ failure. Market trends point towards a shift towards personalized medicine, with a focus on tailoring immunosuppressive regimens based on individual patient characteristics and genetic profiles to minimize the risk of rejection while reducing adverse events. The adoption of innovative drug delivery systems, such as extended-release formulations and targeted therapies, is also gaining momentum. Despite these positive advancements, restraints such as the high cost of treatments, potential side effects associated with immunosuppressants, and the risk of infections in transplant recipients continue to pose challenges. The competitive landscape is dominated by established pharmaceutical giants, including Novartis AG, Astellas Pharma, Inc., CSC Pharmaceuticals, F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi, who are actively engaged in research and development to maintain their market share and introduce next-generation therapies. The market is segmented by drug class, indication, route of administration, and geography, each segment contributing uniquely to the overall market dynamics and growth trajectory.

BackgroundOrgan donation shortage and in particular organ procurement is an international concern as the gap between the number of donors and recipients is steadily growing. Organ procurement is a chain of steps with donor identification and referral (ID&R) as the very first link in this chain. Failure of this step hinders the progress in the organ transplantation program.ObjectivesOur study was conducted to evaluate and highlight the gap between the national system and the practice at the identification and referral (ID&R) step of the organ procurement chain in a single tertiary-care academic health center in Beirut: the Lebanese American University Medical Center–Rizk Hospital (LAUMC-RH), and to appraise the literature for challenges at this step and for possible interventions for improvement based on the international experience.Materials and methodsThis retrospective study was a descriptive case series of ICU and ED deceased patients at a single tertiary-care university hospital in Beirut. Patients’ characteristics were collected from medical records for all patients who died between 2017 and 2019 while in the ICU or the ED and shared with the National Organization for Organ and Tissue Donation and Transplantation (NOD-Lb), for each subject separately, to decide on the donor status. All data collected from the patient cohort was analyzed using R version 3.6.1. Wilcoxon signed-rank test, chi-squared, and fisher-exact tests were used to compare differences in clinical characteristics in terms of donor status when appropriate.ResultsThis study served as 3 years audit of a single hospital experience, and it demonstrates failure to make any referrals to NOD-Lb and zero actual organ and tissue donations over the study period. The review of 295 deceased subjects’ charts demonstrates 295 missed alerts to NOD-Lb and the overall missing of 5 organ and tissue donors and 24 cornea donors assuming the organ procurement chain of steps will continue uninterrupted after ID&R.ConclusionThe data gathered suggests the presence of an inefficient identification and referral system that is translated into a complete failure of reporting to NOD-Lb from LAUMC-RH. A systematic evidence-based approach to evaluate for the most cost-effective intervention to increase identification and referral rates is needed with a serious effort to examine and account for any inefficient implantation.

Critical pathway for deceased organ donors, Lebanon 2017–2019 (NOD-Lb).